Neoadjuvant chemotherapy, surgery, and postoperative radiation therapy for invasive thymoma

Macchiarini, Paolo; Chella, Antonio; Ducci, F; Rossi, Bruno; Testi, C; Bevilacqua, Generoso; Angeletti, Ca

doi:10.1002/1097-0142(19910815)68:4<706::aid-cncr2820680407>3.0.co;2-h

Cited by 177 publications

(82 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cisplatin based regimens have also proved to be effective in the treatment [3,9,13,14]. In cases similar to ours, neoadjuvant chemotherapy was proposed to improve the respectability of the mass [17,23]. The average survival time of thymic carcinomas in adult series was about 2.5 years [3,9,13,14].…”

Section: Discussionsupporting

confidence: 63%

Thymic carcinoma in children

Yarış

Nas

Çobanoğlu

et al. 2005

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Thymic epithelial neoplasms consist of thymomas, thymic carcinoids, and thymic carcinomas. Carcinomas are malignant tumors of the thymus characterized by obvious cytological anaplasia. They constitute only 4%–14% of thymic epithelial neoplams. Thymic carcinoma rarely occurs in children. Research in the English literature carried out for the present study revealed only 14 cases younger than 18 years‐of‐age. Here we have reported a 16‐year old girl who presented with respiratory distress due to huge anterior mediastinal mass. Histological and immunohistochemical studies confirmed lymphoepithelioma‐like thymic carcinoma. She received systemic chemotherapy and radiotherapy. However, she died within 15 months due to progressive disease. © 2005 Wiley‐Liss, Inc.

show abstract

Section: Discussionsupporting

confidence: 63%

Thymic carcinoma in children

Yarış

Nas

Çobanoğlu

et al. 2005

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…It has been shown that certain chemotherapy regimens can sterilize thymoma. In a study reported by Macchiarini and colleagues, seven patients with clinically stage III invasive thymoma were given neoadjuvant cisplatin, epirubicin, and etoposide [50]. All seven patients subsequently underwent surgical resection-four complete and three incomplete.…”

Section: Multimodality Therapymentioning

confidence: 99%

Thymoma: Update for the New Millenium

et al. 2001

View full text Add to dashboard Cite

USA. Telephone: 210-616-5648; Fax: 210-949-5085; e-mail: cthomas@saci.org www: cancerdata.com Received October 11, 2000; accepted for publication May 11, 2001. ©AlphaMed Press 1083-7159/2001 INTRODUCTIONThymic tumors are common among anterior mediastinal tumors in adults. The vast majority of thymic lesions are thymoma [1]. Thymoma is relatively unique among tumors in that the prognosis appears to be more closely related to the invasive characteristics seen at operation rather than histological appearance. Indeed, the degree of encapsulation and invasion of adjacent tissues define malignancy for these tumors rather than the histologic appearance of the tumor cells [2]. Current treatment of thymoma is often multidisciplinary in nature, and has evolved based upon a growing number of studies to date. These studies have looked at various outcomes based upon associated patient syndromes, tumor histology, and tumor staging, as well as various surgical, radiotherapeutic, chemotherapeutic, and multimodality trials. These studies form the basis of this review.

show abstract

“…Several chemotherapy regimens have been used in this setting, mostly consisting of adriamycin-and/or platin-based multi-agent combinations (table 4, fig. 2) [78][79][80][81][82][83][84][85][86][87][88]. Usually two to four cycles of chemotherapy are administered before imaging reassessment.…”

Section: Chemotherapy Principlesmentioning

confidence: 99%

Thymic epithelial tumours: from basic principles to individualised treatment strategies

Girard¹

2013

European Respiratory Review

View full text Add to dashboard Cite

Thymic epithelial tumours represent a wide range of anatomical, clinical, histological and molecular malignant entities that may be aggressive and difficult to treat. The histopathological classification distinguishes thymomas from thymic carcinomas. Thymomas may be associated with autoimmune disorders.The management of thymic epithelial tumours is a paradigm of co-operation between clinicians, surgeons and pathologists, from establishing the diagnosis to organising the multimodal therapeutic strategy. Surgery is the mainstay of the curative-intent treatment, as complete resection represents the most significantly favourable prognostic factor on overall survival. In case of invasion of intra-thoracic structures and/or dissemination to the pleura and the pericardium, precluding complete resection to be achieved, primary chemotherapy has been used to reduce the tumour burden, possibly allowing subsequent surgery and/or radiotherapy.Novel strategies are needed, especially for refractory, recurrent tumours and thymic carcinomas, which carry a poor prognosis. Personalised approaches are currently being developed, as potentially ''druggable'' molecular targets are emerging from recent integrated genomic analyses. Along with the large variety of questions relative to the treatment strategy, thymic epithelial tumours represent a model of therapeutic implementation and achievement in orphan thoracic oncology, showing how the advent of new results induces new questions, as well as diversifies further clinical research directions and international collaborative initiatives.

show abstract

Neoadjuvant chemotherapy, surgery, and postoperative radiation therapy for invasive thymoma

Cited by 177 publications

References 27 publications

Thymic carcinoma in children

Thymic carcinoma in children

Thymoma: Update for the New Millenium

Thymic epithelial tumours: from basic principles to individualised treatment strategies

Contact Info

Product

Resources

About